Today, the European Commission published, at the request of the Council, a study on New Genomic Techniques (NGTs).
It is associated to a dashboard on the EC's Data/Modelling agro-economic platform (DataM).
Know more...
EU science hub: New genomic techniques: where do we stand?
EUROPA site, food safety section: EC study on new genomic techniques
EC press release: Biotechnologies: Commission seeks open debate on New Genomic Techniques as study shows potential for sustainable agriculture and need for new policy
The report
Title: Current and future market applications of new genomic techniques
URL: https://doi.org/10.2760/02472
Authors: Parisi, C; Rodríguez-Cerezo, E
Journal: Publications office of the European Union
Abstract:
This report presents a review of market applications of new genomic techniques (NGTs). For the purposes of this study, NGTs are defined as ‘techniques that are able to alter the genetic material of an organism, developed after the publication of EU Directive 2001/18/EC’.
The study covers NGT applications in agri-food, industrial and medicinal sectors that have resulted in applications that are already being marketed, are at a confirmed pre-market development stage or are at a research and development (R & D) stage but showing market potential. The scope includes the use of NGTs in any kind of plant, mushroom, animal or microorganism or in human cells.
Data on NGT applications were collected from multiple sources, including information available online, consultation of experts and an ad hoc survey of public and private technology developers. The NGT applications identified were classified, using the information available, as being at the following development stages.
- Commercial stage. NGT applications currently marketed in at least one country worldwide.
- Pre-commercial stage. NGT applications ready to be commercialised in at least one country worldwide but not yet on the market (commercialisation mainly depends on the developer’s decision and a 5-year horizon is estimated).
- Advanced R& D stage. NGT applications at a late stage of development (field trials in the case of plants, in/ex vivo clinical trials in the case of medical applications) and likely to reach the market in the medium term (i.e. by 2030).
- Early R& D stage. NGT applications at proof of concept stage (i.e. testing gene targets for trait enhancement of commercial interest).
NGTs, especially those based on clustered regularly interspaced short palindromic repeats (CRISPR), are being actively and increasingly used in all the sectors analysed. Currently, few NGT applications are marketed worldwide: one plant product, one microorganism for release into the environment and several microorganisms used for contained production of commercial molecules. There are, however, about 30 identified applications (in plants, animals and microorganisms) at a pre-commercial stage in the pipeline that could reach the market in the short term (within 5 years). In addition, the medicinal sector is actively using NGTs to tackle several human diseases, and in many cases applications have already reached patients, in phase I and phase I/II clinical trials.
The dashboard
Title: New Genomic Techniques (NGTs)
URL: https://datam.jrc.ec.europa.eu/datam/mashup/NEW_GENOMIC_TECHNIQUES
DataM
You can find this dashboard and publication in the DataM sections for: Technologies in agriculture and Bioeconomy
Find the paper also in: the DataM publications navigator
